A Multicenter, Randomized, Open-label, Two-arm, Phase 4 Study to Evaluate the Effect of Add-on Pioglitazone or Dapagliflozin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Alogliptin/pioglitazone (Primary) ; Alogliptin; Dapagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EPIDOTE
- Sponsors Takeda
- 02 Dec 2019 Planned number of patients changed from 176 to 232.
- 02 Dec 2019 Planned End Date changed from 31 Dec 2020 to 5 Jan 2022.
- 02 Dec 2019 Planned primary completion date changed from 26 Jun 2020 to 22 Dec 2021.